FindTrial
Sign In

SPK-8016

GENETIC2 trials

Sponsors

Spark Therapeutics, Inc.

Conditions

Adeno-Associated Virus (AAV)Blood Coagulation DisorderBlood Coagulation Disorders, InheritedCoagulation Protein DisordersFactor VIII (FVIII)Factor VIII (FVIII) DeficiencyFactor VIII (FVIII) GeneFactor VIII (FVIII) Protein

Phase 1

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
CompletedNCT03734588
Spark Therapeutics, Inc.Adeno-Associated Virus (AAV), Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited +14
Start: 2019-01-30End: 2023-01-19Updated: 2024-02-23

Unknown Phase

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
Active, not recruitingNCT03432520
Spark Therapeutics, Inc.Hemophilia A
Start: 2018-08-14End: 2032-12-31Updated: 2024-11-29

Related Papers

Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A
Blood Advances2024-07-183 citations
Long-Term FVIII Expression with Reduced Bleeding Following Gene Transfer for Hemophilia A: Follow-up on the Dirloctocogene Samoparvovec Phase I/II Trial
Hämostaseologie2024-02-011 citations
Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
Blood2022-11-156 citations
Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A
Blood2022-11-151 citations
The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011
Blood2022-11-15
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
New England Journal of Medicine2021-11-17232 citations